fusidic acid has been researched along with levofloxacin in 10 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 4,346 | 581 | 2,209 |
| Protein | Taxonomy | fusidic acid (IC50) | levofloxacin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; KoĊĦmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Ashenden, S; Bender, A; Cokol, M; Karakoc, I; Kuru, N; Mason, DJ; Meral, S; Stott, I; Weinstein, ZB | 1 |
| Akhir, A; Chopra, S; Kaul, G; Meenu, MT; Radhakrishnan, KV; Shukla, M | 1 |
| Bryskier, A; Capper, T; Klugman, KP | 1 |
| Kamel, AG; Lim, VK; Norazah, A; Rohani, MY | 1 |
| Bourgeois-Nicolaos, N; Cattoir, V; Decousser, JW; Desroches, M; Doucet-Populaire, F; Jehl, F; Lina, G; Potier, J; Vandenesh, F | 1 |
10 other study(ies) available for fusidic acid and levofloxacin
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
Topics: Anti-Bacterial Agents; Drug Interactions; Molecular Structure | 2017 |
Developing the Natural Prenylflavone Artocarpin from
Topics: Animals; Anti-Bacterial Agents; Artocarpus; Biofilms; Flavonoids; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2022 |
In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.
Topics: Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Fusidic Acid; Levofloxacin; Mutation; Ofloxacin; Penicillin Resistance; Rifampin; Streptococcus pneumoniae; Teicoplanin; Vancomycin | 1996 |
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin | 2005 |
Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Coagulase; Drug Resistance, Multiple, Bacterial; France; Fusidic Acid; Gentamicins; Hospitals; Humans; Levofloxacin; Linezolid; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prospective Studies; Rifampin; RNA, Ribosomal, 23S; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staphylococcal Infections; Staphylococcus epidermidis | 2015 |